This World Heart Day, we are proud to partner with the World Heart Federation to support their mission to achieve heart health equity for all.
At Pfizer, we are united by a single purpose – to deliver breakthroughs that change patients’ lives. Every day, Pfizer colleagues from around the world work to address areas of significant unmet medical need. Nowhere is this need greater than in rare disease.
There are more than 7,000 known rare diseases. One of these is called transthyretin amyloid cardiomyopathy or ATTR-CM, which is a form of cardiac amyloidosis. ATTR-CM is a rare, underdiagnosed, and fatal condition, resulting in progressive heart failure.
This year, we continue our partnership with the World Heart Federation to support the cardiology community and share how we at Pfizer, ‘use heart.’ We ‘use heart’ to pioneer innovation. We ‘use heart’ to champion health equity. We ‘use heart’ to improve care for all those living with cardiovascular disease, including those living with rare conditions, such as ATTR-CM. This year, we hope to inspire others to share how they ‘use heart’ to support the cardiac amyloidosis community.